<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292431</url>
  </required_header>
  <id_info>
    <org_study_id>MOCORSEP_BEC_2019</org_study_id>
    <nct_id>NCT04292431</nct_id>
  </id_info>
  <brief_title>Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)</brief_title>
  <acronym>MOCORSEP</acronym>
  <official_title>Exploration of Variations in Leukocyte Morphological Parameters (MDW and CPD) Using the Beckman Coulter DxH900, Based on the Infectious Condition, Inflammatory State and Response to Corticosteroid Therapy in Septic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital Raymond Poincaré</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint-Louis Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, prospective, monocentric study on the exploration of leukocyte
      morphological parameters according to the infectious condition and response to corticosteroid
      therapy of septic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is a major public health issue, caused by an organ disorder related to an immune
      response not controlled by the infection.

      Several randomized trials have shown that the combination of glucocorticoids and
      mineralocorticoids improves the survival rate of patients in septic shock. The optimal use of
      this therapeutic approach requires identifying the pro-inflammatory phase patients likely to
      respond to corticosteroid therapy.

      Hyperactivation of immune cells is accompanied by morphological changes likely to be
      characterized by modern hematology instruments, particularly the DxH900 (Beckman Coulter).
      The DxH900 is able to use specific techniques to determine a significant number of
      morphological characteristics (CPD or Cell Population Data) for circulating leukocytes.
      Recently, one of these leukocyte morphological parameters, MDW (Monocyte Distribution Width),
      has been clinically approved for identifying septic patients or those at risk of developing
      sepsis. This MDW parameter currently has the CE IVD mark and is approved by the American FDA.

      The aim of the study is to explore the hypothesis that leukocyte morphological parameters,
      including MDW, may constitute functional biomarkers of pro-inflammatory response and help to
      identify septic patients likely to optimally respond to a combination treatment of
      glucocorticoids and mineralocorticoids, and thus improve their chances of survival.

      The proposed study is a non-interventional, prospective, monocentric cohort study to explore
      the variation of leukocyte morphological parameters measured on the DxH900 hematology
      analyzer according to the different infectious conditions of patients ranging from a known or
      suspected infection to septic shock versus non-infected control patients, and possibly based
      on the response. This observational cohort study will consist of patients with a known or
      suspected infection, sepsis or in septic shock on their date of admission into one of the
      medical or surgical departments and monitored up to day 7 of the hospital stay or on the date
      of discharge from the hospital, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>Leukocytes morphological parameters differs between patient's groups</measure>
    <time_frame>7 days</time_frame>
    <description>The leukocytes morphological parameters determined by DxH900 (CPD and MDW) will be compared between the patient's groups in the cohort:
patients with infection
patients with sepsis
patients with septic shock
patients with septic shock responding to corticosteroid treatment
patients with septic shock not responding to corticosteroid treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukocytes morphological parameters preditcs inflammatory status</measure>
    <time_frame>7 days</time_frame>
    <description>Identify whether the CPD parameters differ between patients with a pro-inflammatory state for those presenting signs of immunosuppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes morphological parameters preditcs responce to corticosteroids treatments</measure>
    <time_frame>7 days</time_frame>
    <description>Explore the relevance of CPD parameters for predicting and monitoring the response to corticosteroid therapy in patients with septic shock.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Sepsis Syndrome</condition>
  <condition>Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Non infected (n=50) Infection (n=50) Sepsis + SOFA &gt; 2 (n=25) Sepsis (SOFA &gt; 2) +
        vasopressors and lactate ≤ 2 mmol/L (n=25) Septic shock (SOFA &gt; 2 + vasopressor + lactate &gt;
        2 mmol/L) (n=25)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  an infection (known or suspected)

          -  sepsis

          -  sepsis + vasopressor

          -  septic shock

               -  responders to corticosteroid therapy

               -  non-responders to corticosteroid therapy

        Exclusion Criteria:

          -  Pregnant women

          -  Patients with onco-hematological diseases with the presence of blasts.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali Annane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Raymond Poincaré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Moine, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Raymond Poincaré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Rottman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Raymond Poincaré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvie Chevret, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Saint Louis Lariboisière Fernand-Widal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naima Imam, PhD</last_name>
    <phone>+33171167728</phone>
    <email>naima.imam@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Djillali Annane, MD</last_name>
    <phone>+33147107823</phone>
    <email>djillali.annane@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <state>Paris</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naima Imam, PhD</last_name>
      <phone>+33171167728</phone>
      <email>naima.imam@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Djilali Annane, MD</last_name>
      <phone>+33147107823</phone>
      <email>djillali.annane@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E; CRICS-TRIGGERSEP Network. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018 Mar 1;378(9):809-818. doi: 10.1056/NEJMoa1705716.</citation>
    <PMID>29490185</PMID>
  </reference>
  <reference>
    <citation>Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002 Aug 21;288(7):862-71. Erratum in: JAMA. 2008 Oct 8;300(14):1652. Chaumet-Riffaut, Philippe [corrected to Chaumet-Riffaud, Philippe].</citation>
    <PMID>12186604</PMID>
  </reference>
  <reference>
    <citation>Crouser ED, Parrillo JE, Seymour C, Angus DC, Bicking K, Tejidor L, Magari R, Careaga D, Williams J, Closser DR, Samoszuk M, Herren L, Robart E, Chaves F. Improved Early Detection of Sepsis in the ED With a Novel Monocyte Distribution Width Biomarker. Chest. 2017 Sep;152(3):518-526. doi: 10.1016/j.chest.2017.05.039. Epub 2017 Jun 15.</citation>
    <PMID>28625579</PMID>
  </reference>
  <reference>
    <citation>Crouser ED, Parrillo JE, Seymour CW, Angus DC, Bicking K, Esguerra VG, Peck-Palmer OM, Magari RT, Julian MW, Kleven JM, Raj PJ, Procopio G, Careaga D, Tejidor L. Monocyte Distribution Width: A Novel Indicator of Sepsis-2 and Sepsis-3 in High-Risk Emergency Department Patients. Crit Care Med. 2019 Aug;47(8):1018-1025. doi: 10.1097/CCM.0000000000003799.</citation>
    <PMID>31107278</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukocyte morphology</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>MDW</keyword>
  <keyword>Cell population data</keyword>
  <keyword>DxH900</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

